Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Zarontin (ethosuxide) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

May 2012

Summary View

WARNINGS

Serious Dermatologic Reactions
  • Serious dermatologic reactions, including with ethosuximide treatment. SJS can be fatal. The onset of symptoms is usually within 28 days, but can occur later. Zarontin should be discontinued at the first sign of a rash, unless symptoms suggest SJS, use of this drug should considered

PRECAUTIONS

Information for Patients
  • Prior to initiation of treatment with Zarontin, the patient should be instructed that a rash may herald a serious medical event and that the patient should report any such occurrence to a physician immediately

ADVERSE REACTIONS

Body as a Whole
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

 

 

September 2010

Summary View

 

MEDICATIONS GUIDE 

  • REMS consists of a comprehensive Medication Guide

 

-
-